Coherus Oncology (CHRS) Times Interest Earned (2013 - 2026)
Coherus Oncology's (CHRS) quarterly Times Interest Earned came in at -$16.54 in Q1 2026, up 21.74% year-on-year from -$13.58 in Q1 2025, and down 138.42% quarter-over-quarter from $43.04 in Q4 2025.
Coherus Oncology (CHRS) Times Interest Earned (2013 - 2026) Analysis & Trends
Coherus Oncology has disclosed Times Interest Earned across 14 years of filings, most recently posting -$16.54 for Q1 2026.
- Times Interest Earned for Q1 2026 came in at -$16.54, up 21.74% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.23 (up 80.06% YoY), and the FY2025 annual result was -$4.27, up 77.03% from the prior year.
- Times Interest Earned came in at -$16.54 for Q1 2026 at Coherus Oncology, down from $43.04 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $43.04 in Q4 2025 to a low of -$23.74 in Q4 2024.
- The 5-year median for Times Interest Earned is -$9.76 (2024), against an average of -$9.26.
- Across the five-year window, Times Interest Earned sank 431.73% in 2024 and surged 281.33% in 2025, its largest moves.
- Coherus Oncology's Times Interest Earned stood at -$5.49 in 2022, then slipped by 18.26% to -$6.49 in 2023, then tumbled by 265.8% to -$23.74 in 2024, then surged by 281.33% to $43.04 in 2025, then tumbled by 138.42% to -$16.54 in 2026.
- The last three Times Interest Earned figures came in at -$16.54 (Q1 2026), $43.04 (Q4 2025), and -$19.07 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Coherus Oncology | 199.14 Mn | 32.09 Mn | 8.50 Mn | -16.54 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.54 |
| Dec 31, 2025 | 43.04 |
| Sep 30, 2025 | -19.07 |
| Jun 30, 2025 | -19.98 |
| Mar 31, 2025 | -21.13 |
| Dec 31, 2024 | -23.74 |
| Sep 30, 2024 | -16.57 |
| Jun 30, 2024 | -9.76 |
| Mar 31, 2024 | -21.74 |
| Dec 31, 2023 | -6.49 |
| Sep 30, 2023 | -3.12 |
| Jun 30, 2023 | -3.47 |
| Mar 31, 2023 | -6.98 |
| Dec 31, 2022 | -5.49 |
| Sep 30, 2022 | -10.67 |
| Jun 30, 2022 | -6.69 |
| Mar 31, 2022 | -9.02 |
| Dec 31, 2021 | -6.83 |
| Sep 30, 2021 | -5.68 |
| Jun 30, 2021 | -4.20 |